Ortho's Suprol
Executive Summary
Decision is to be made by FDA within three months on a 1983 submission of a "new claim" for the NSAID, according to an agency memorandum of a Sept. 7 meeting between J&J and FDA. The drug is indicated for "mild to moderate pain" and is currently marketed in Europe